Issued 2026-08-13 at $71.50 · now $84.04 (2026-08-13, +17.5% since)
Based on its own history, a month from the 2026-08-13 close, SLGL has typically landed between $50.98 and $109.48 — a range of −28.7% to +53.1% from the issuance price $71.50.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
2,121 overlapping 1 month windows · 2018-02-01 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($71.50) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where SLGL has typically landed a month from the 2026-08-13 close of $71.5 — the range is history, not a prediction.
- now $84.04 (+17.5%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $69.04 (-3.4%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $60.66–$77.42
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $50.98–$109.48
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2024-07-12 | −60.9% | −61.9% | +0.0% |
| 2024-07-09 | −59.7% | −59.7% | +3.2% |
| 2024-07-11 | −58.0% | −58.0% | +10.2% |
| 3 best | |||
| 2024-12-04 | +174.5% | −15.9% | +174.5% |
| 2025-07-23 | +159.6% | +0.0% | +159.6% |
| 2024-12-11 | +154.4% | −16.0% | +174.0% |
2,121 overlapping windows · 2018-02-01 – 2026-08-13 · not cherry-picked
Pending catalysts
- October 2026 — Trial primary completion: Phase 3 primary completion: Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~9 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.